Gapping up
In reaction to strong earnings/guidance: CLF +11.1%, FB +10.9%, (also announces proposal of new class of stock), CVEO+10.4%, DLB +9.5%, EXTR +9.1%, ANIK +7.8%, PPC +6.9%, (also declares special dividend of $2.75/share), NTGR+6.8%, TTMI +6.8%, RNG +6.2%, VALE +5.9%, INUV +5.3%, YNDX +4.7%, BGC +4.1%, ASGN +3.7%, NGD +3.3%,SPRT +3.2%, CSH +3.2%, CSGP +3.1%, ELY +2.9%, INSY +2.6%, NEFF +2%, HTCH +1.9%, GG +1.9%, PYPL +1.8%,MAR +1.8%, F +1.8%, BMY +1.8%, DB +1.7%, F +1.7%, NOV +1.6%, SNDK +1.5%, TXN +1.4%, ALGT +1.3%, (also increases buyback authorization to $100 mln; increase quarterly dividend to $0.70 per share), VIV +1.3%, TOWR +1.2%, MO+1.1%, KIM +1%, CAB +1%, UPS +1%, BXLT +1%, CAKE +0.9%, LQ +0.9%
M&A news: TXTR +30% (acquired by Oracle (ORCL) for $26.00/share in cash or ~$663 mln), STJ +25.6% (Abbott (ABT) to acquire St. Jude Medical for $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of ~$85/share), MEMP +11.1% (Memorial Resource Development sells Memorial Production Partners GP to Memorial Production Partners (MEMP) for $750K in cash), MDVN +7.6% (receives hostile bid from Sanofi (SNY) for $52.50 per share), QLIK +4.8% (received preliminary takeover offers from various PE firms, according to Bloomberg), ALR +2.6% (ABT acquisition of STJ contemplates financing capacity to close both transactions)
Select metals/mining stocks trading higher: GFI +3.4%, SBGL +3%, HMY +2.1%, NEM +2%, AUY +1.6%, MT +1.1%,GDX +0.9%, RIO +0.9%, GLD +0.8%, AG +0.7%, ABX +0.7%
Other news: AEZS +15.5% (acquires exclusive US promotional rights for Apifiny prostate cancer blood test pursuant to a new co-marketing agreement with Armune BioScience), ADMS +8.6% (announces 'positive' top-line results from its phase 3 EASE lid 3 trial of ADS-5102; met its primary and key secondary endpoints), HBI +4.6% (approves a new share repurchase authorization for up to 40 mln shares ), ACTG +3.4% (CEO disclosed purchase of 55K shares worth total of $228.1K and Director purchased of 35K shares for $144.6K ), VRX +2.8% (expected to announce as early as Friday an overhaul of its Board of Directors, according to the WSJ), NVO +2.6% (announces top-line results from global phase 3a trial, notes that semaglutide 'significantly' reduces the risk of major adverse cardiovascular events), CATM +2% (Cardtronics to redomicile in the United Kingdom, expects adjustment from FY16 non-GAAP earnings), AMID +1.4% (announces acquisition of 66.7% interest in Okeanos pipeline, financial terms undisclosed), USCR +1.1% ( will restate its financial statements for the year ended December 31, 2015 in relation to its $24.8 million deferred tax asset )
Analyst comments: AAL +1.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
In reaction to strong earnings/guidance: CLF +11.1%, FB +10.9%, (also announces proposal of new class of stock), CVEO+10.4%, DLB +9.5%, EXTR +9.1%, ANIK +7.8%, PPC +6.9%, (also declares special dividend of $2.75/share), NTGR+6.8%, TTMI +6.8%, RNG +6.2%, VALE +5.9%, INUV +5.3%, YNDX +4.7%, BGC +4.1%, ASGN +3.7%, NGD +3.3%,SPRT +3.2%, CSH +3.2%, CSGP +3.1%, ELY +2.9%, INSY +2.6%, NEFF +2%, HTCH +1.9%, GG +1.9%, PYPL +1.8%,MAR +1.8%, F +1.8%, BMY +1.8%, DB +1.7%, F +1.7%, NOV +1.6%, SNDK +1.5%, TXN +1.4%, ALGT +1.3%, (also increases buyback authorization to $100 mln; increase quarterly dividend to $0.70 per share), VIV +1.3%, TOWR +1.2%, MO+1.1%, KIM +1%, CAB +1%, UPS +1%, BXLT +1%, CAKE +0.9%, LQ +0.9%
M&A news: TXTR +30% (acquired by Oracle (ORCL) for $26.00/share in cash or ~$663 mln), STJ +25.6% (Abbott (ABT) to acquire St. Jude Medical for $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of ~$85/share), MEMP +11.1% (Memorial Resource Development sells Memorial Production Partners GP to Memorial Production Partners (MEMP) for $750K in cash), MDVN +7.6% (receives hostile bid from Sanofi (SNY) for $52.50 per share), QLIK +4.8% (received preliminary takeover offers from various PE firms, according to Bloomberg), ALR +2.6% (ABT acquisition of STJ contemplates financing capacity to close both transactions)
Select metals/mining stocks trading higher: GFI +3.4%, SBGL +3%, HMY +2.1%, NEM +2%, AUY +1.6%, MT +1.1%,GDX +0.9%, RIO +0.9%, GLD +0.8%, AG +0.7%, ABX +0.7%
Other news: AEZS +15.5% (acquires exclusive US promotional rights for Apifiny prostate cancer blood test pursuant to a new co-marketing agreement with Armune BioScience), ADMS +8.6% (announces 'positive' top-line results from its phase 3 EASE lid 3 trial of ADS-5102; met its primary and key secondary endpoints), HBI +4.6% (approves a new share repurchase authorization for up to 40 mln shares ), ACTG +3.4% (CEO disclosed purchase of 55K shares worth total of $228.1K and Director purchased of 35K shares for $144.6K ), VRX +2.8% (expected to announce as early as Friday an overhaul of its Board of Directors, according to the WSJ), NVO +2.6% (announces top-line results from global phase 3a trial, notes that semaglutide 'significantly' reduces the risk of major adverse cardiovascular events), CATM +2% (Cardtronics to redomicile in the United Kingdom, expects adjustment from FY16 non-GAAP earnings), AMID +1.4% (announces acquisition of 66.7% interest in Okeanos pipeline, financial terms undisclosed), USCR +1.1% ( will restate its financial statements for the year ended December 31, 2015 in relation to its $24.8 million deferred tax asset )
Analyst comments: AAL +1.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)